Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875524 | 0.89 | WHR1 (0.55) | WHR1KDM4ESTAT6NPSR1HSP90AA1 | |
| SCHEMBL875525 | 0.87 | WHR1 (0.47) | WHR1KDM4ESTAT6NPSR1HSP90AA1 | |
| SCHEMBL875523 | 0.86 | WHR1 (0.51) | WHR1KDM4ESTAT6NPSR1HSP90AA1 | |
| SCHEMBL873959 | 0.81 | GUSB (0.53) | KDM4ETSHRAMY1AMAPTMEN1 | |
| SCHEMBL29589069 | 0.78 | WHR1 (0.71) | WHR1KDM4ESTAT6NPSR1LMNA | |
| SCHEMBL20771102 | 0.78 | WHR1 (0.71) | WHR1KDM4ESTAT6NPSR1LMNA | |
| SCHEMBL11917056 | 0.78 | DHFR (0.39) | WHR1NPSR1TSPOLMNAMAPK1 | |
| SCHEMBL873872 | 0.77 | POLB (0.53) | LMNAGAAMAPTMEN1KMT2A | |
| SCHEMBL5575014 | 0.76 | ABCG2 (0.44) | LMNAMAPTMEN1KMT2AABCG2 | |
| SCHEMBL3122813 | 0.76 | METAP1 (0.46) | NPSR1TSPOMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-2406236-A1 | RHO KINASE INHIBITORS | Surface Logix, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | WHR1 4028/4885KDM4E 3007/4885STAT6 3054/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | WHR1 4028/4885KDM4E 3007/4885STAT6 3054/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | WHR1 4028/4885KDM4E 3007/4885STAT6 3054/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | WHR1 4028/4885KDM4E 3007/4885STAT6 3054/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | WHR1 4028/4885KDM4E 3007/4885STAT6 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.